Cargando…
Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer
Enzalutamide (ENZA) is a frequently used therapy in metastatic castration‐resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to identify proteins involved in ENZA resistance and to...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539937/ https://www.ncbi.nlm.nih.gov/pubmed/35689436 http://dx.doi.org/10.1002/ijc.34159 |
_version_ | 1784803601058627584 |
---|---|
author | Csizmarik, Anita Keresztes, Dávid Nagy, Nikolett Bracht, Thilo Sitek, Barbara Witzke, Kathrin Puhr, Martin Tornyi, Ilona Lázár, József Takács, László Kramer, Gero Sevcenco, Sabina Maj‐Hes, Agnieszka Jurányi, Zsolt Hadaschik, Boris Nyirády, Péter Szarvas, Tibor |
author_facet | Csizmarik, Anita Keresztes, Dávid Nagy, Nikolett Bracht, Thilo Sitek, Barbara Witzke, Kathrin Puhr, Martin Tornyi, Ilona Lázár, József Takács, László Kramer, Gero Sevcenco, Sabina Maj‐Hes, Agnieszka Jurányi, Zsolt Hadaschik, Boris Nyirády, Péter Szarvas, Tibor |
author_sort | Csizmarik, Anita |
collection | PubMed |
description | Enzalutamide (ENZA) is a frequently used therapy in metastatic castration‐resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to identify proteins involved in ENZA resistance and to find therapy‐predictive serum markers. We performed comparative proteome analyses on ENZA‐sensitive parental (LAPC4, DuCaP) and ‐resistant prostate cancer cell lines (LAPC4‐ENZA, DuCaP‐ENZA) using liquid chromatography tandem mass spectrometry (LC‐MS/MS). The top four most promising candidate markers were selected using bioinformatic approaches. Serum concentrations of selected markers (ALCAM, AGR2, NDRG1, IDH1) were measured in pretreatment samples of 72 ENZA‐treated mCRPC patients using ELISA. In addition, ALCAM serum levels were measured in 101 Abiraterone (ABI) and 100 Docetaxel (DOC)‐treated mCRPC patients' baseline samples. Results were correlated with clinical and follow‐up data. The functional role of ALCAM in ENZA resistance was assessed in vitro using siRNA. Our proteome analyses revealed 731 significantly differentially abundant proteins between ENZA‐sensitive and ‐resistant cells and our filtering methods identified four biomarker candidates. Serum analyses of these proteins revealed only ALCAM to be associated with poor patient survival. Furthermore, higher baseline ALCAM levels were associated with poor survival in ABI‐ but not in DOC‐treated patients. In LAPC4‐ENZA resistant cells, ALCAM silencing by siRNA knockdown resulted in significantly enhanced ENZA sensitivity. Our analyses revealed that ALCAM serum levels may help to identify ENZA‐ and ABI‐resistant patients and may thereby help to optimize future clinical decision‐making. Our functional analyses suggest the possible involvement of ALCAM in ENZA resistance. |
format | Online Article Text |
id | pubmed-9539937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95399372022-10-14 Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer Csizmarik, Anita Keresztes, Dávid Nagy, Nikolett Bracht, Thilo Sitek, Barbara Witzke, Kathrin Puhr, Martin Tornyi, Ilona Lázár, József Takács, László Kramer, Gero Sevcenco, Sabina Maj‐Hes, Agnieszka Jurányi, Zsolt Hadaschik, Boris Nyirády, Péter Szarvas, Tibor Int J Cancer Tumor Markers and Signatures Enzalutamide (ENZA) is a frequently used therapy in metastatic castration‐resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to identify proteins involved in ENZA resistance and to find therapy‐predictive serum markers. We performed comparative proteome analyses on ENZA‐sensitive parental (LAPC4, DuCaP) and ‐resistant prostate cancer cell lines (LAPC4‐ENZA, DuCaP‐ENZA) using liquid chromatography tandem mass spectrometry (LC‐MS/MS). The top four most promising candidate markers were selected using bioinformatic approaches. Serum concentrations of selected markers (ALCAM, AGR2, NDRG1, IDH1) were measured in pretreatment samples of 72 ENZA‐treated mCRPC patients using ELISA. In addition, ALCAM serum levels were measured in 101 Abiraterone (ABI) and 100 Docetaxel (DOC)‐treated mCRPC patients' baseline samples. Results were correlated with clinical and follow‐up data. The functional role of ALCAM in ENZA resistance was assessed in vitro using siRNA. Our proteome analyses revealed 731 significantly differentially abundant proteins between ENZA‐sensitive and ‐resistant cells and our filtering methods identified four biomarker candidates. Serum analyses of these proteins revealed only ALCAM to be associated with poor patient survival. Furthermore, higher baseline ALCAM levels were associated with poor survival in ABI‐ but not in DOC‐treated patients. In LAPC4‐ENZA resistant cells, ALCAM silencing by siRNA knockdown resulted in significantly enhanced ENZA sensitivity. Our analyses revealed that ALCAM serum levels may help to identify ENZA‐ and ABI‐resistant patients and may thereby help to optimize future clinical decision‐making. Our functional analyses suggest the possible involvement of ALCAM in ENZA resistance. John Wiley & Sons, Inc. 2022-06-21 2022-10-15 /pmc/articles/PMC9539937/ /pubmed/35689436 http://dx.doi.org/10.1002/ijc.34159 Text en © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Tumor Markers and Signatures Csizmarik, Anita Keresztes, Dávid Nagy, Nikolett Bracht, Thilo Sitek, Barbara Witzke, Kathrin Puhr, Martin Tornyi, Ilona Lázár, József Takács, László Kramer, Gero Sevcenco, Sabina Maj‐Hes, Agnieszka Jurányi, Zsolt Hadaschik, Boris Nyirády, Péter Szarvas, Tibor Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer |
title | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer |
title_full | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer |
title_fullStr | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer |
title_full_unstemmed | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer |
title_short | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer |
title_sort | proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified alcam as marker of resistance in castration‐resistant prostate cancer |
topic | Tumor Markers and Signatures |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539937/ https://www.ncbi.nlm.nih.gov/pubmed/35689436 http://dx.doi.org/10.1002/ijc.34159 |
work_keys_str_mv | AT csizmarikanita proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT keresztesdavid proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT nagynikolett proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT brachtthilo proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT sitekbarbara proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT witzkekathrin proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT puhrmartin proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT tornyiilona proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT lazarjozsef proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT takacslaszlo proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT kramergero proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT sevcencosabina proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT majhesagnieszka proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT juranyizsolt proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT hadaschikboris proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT nyiradypeter proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer AT szarvastibor proteomeprofilingofenzalutamideresistantcelllinesandserumanalysisidentifiedalcamasmarkerofresistanceincastrationresistantprostatecancer |